GC Pharma conducts Phase 2/3 Clinical Trial for GC1102 forbidding hepatitis B virus
GC Pharma, a South Korean biopharmaceutical company affirmed that it will conduct Phase 2/3 clinical trial for GC1102, the company's investigational recombinant hepatitis B immune…
Read More...
Read More...
